Research Analysts Set Expectations for Vaxart, Inc.'s FY2023 Earnings (NASDAQ:VXRT)

Mon., May 15, 2023 | MarketBeat

Vaxart, Inc. (NASDAQ:VXRT - Get Rating) - Analysts at Cantor Fitzgerald boosted their FY2023 earnings per share estimates for Vaxart in a research note issued to investors on Wednesday, May 10th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biotechnology company will post earnings per share of ($0.65) for the year, up from their prior estimate of ($0.81). The consensus estimate for Vaxart's current full-year earnings is ($0.68) per share.

Vaxart Stock Performance

Shares of VXRT stock opened at $1.05 on Monday. The stock's 50-day simple moving average is $0.77 and its 200-day simple moving average is $1.00. The firm has a market capitalization of $142.38 million, a PE ratio of -1.27 and a beta of 0.79. Vaxart has a fifty-two week low of $0.56 and a fifty-two week high of $4.62.

Vaxart (NASDAQ:VXRT - Get Rating) last announced its quarterly earnings data on Wednesday, March 15th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.04. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.15 million.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in shares of Vaxart by 15.2% in the second quarter. JPMorgan Chase & Co. now owns 67,047 shares of the biotechnology company's stock valued at $235,000 after acquiring an additional 8,844 shares in the last quarter. Private Portfolio Partners LLC increased its position in Vaxart by 7.3% during the 3rd quarter. Private Portfolio Partners LLC now owns 143,350 shares of the biotechnology company's stock worth $313,000 after purchasing an additional 9,800 shares during the period. Moors & Cabot Inc. grew its holdings in shares of Vaxart by 100.0% in the 3rd quarter. Moors & Cabot Inc. now owns 20,000 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 10,000 shares during the period. IHT Wealth Management LLC grew its holdings in Vaxart by 4.1% during the 3rd quarter. IHT Wealth Management LLC now owns 270,325 shares of the biotechnology company's stock valued at $589,000 after buying an additional 10,546 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its holdings in shares of Vaxart by 17.7% during the third quarter. E Fund Management Co. Ltd. now owns 72,516 shares of the biotechnology company's stock worth $158,000 after purchasing an additional 10,902 shares during the last quarter. 38.66% of the stock is owned by institutional investors and hedge funds.

Vaxart Company Profile

(Get Rating)

Vaxart, Inc operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection.

Should you invest $1,000 in Vaxart right now?

Before you consider Vaxart, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxart wasn't on the list.

While Vaxart currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here